Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

212 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases.
Di Giacomo AM, Chiarion-Sileni V, Del Vecchio M, Ferrucci PF, Guida M, Quaglino P, Guidoboni M, Marchetti P, Cutaia O, Amato G, Covre A, Camerini R, Calabrò L, Valente M, Giannarelli D, Mandalà M, Maio M. Di Giacomo AM, et al. Clin Cancer Res. 2021 Sep 1;27(17):4737-4745. doi: 10.1158/1078-0432.CCR-21-1046. Epub 2021 Jun 10. Clin Cancer Res. 2021. PMID: 34112708 Clinical Trial.
Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial.
Ridolfi R, Chiarion-Sileni V, Guida M, Romanini A, Labianca R, Freschi A, Lo Re G, Nortilli R, Brugnara S, Vitali P, Nanni O; Italian Melanoma Intergroup. Ridolfi R, et al. J Clin Oncol. 2002 Mar 15;20(6):1600-7. doi: 10.1200/JCO.2002.20.6.1600. J Clin Oncol. 2002. PMID: 11896110 Clinical Trial.
Brain metastases from malignant melanoma.
Chiarion-Sileni V, Murr R, Pigozzo J, Sarti S, Tomassi O, Romanini A. Chiarion-Sileni V, et al. Forum (Genova). 2003;13(2):170-82; quiz 190. Forum (Genova). 2003. PMID: 14732883 Review.
Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI - Mel.A.) [ISRCTN75125874].
Chiarion-Sileni V, Del Bianco P, Romanini A, Guida M, Paccagnella A, Dalla Palma M, Naglieri E, Ridolfi R, Silvestri B, Michiara M, De Salvo GL. Chiarion-Sileni V, et al. BMC Cancer. 2006 Feb 27;6:44. doi: 10.1186/1471-2407-6-44. BMC Cancer. 2006. PMID: 16504154 Free PMC article. Clinical Trial.
Basal level and behaviour of cytokines in a randomized outpatient trial comparing chemotherapy and biochemotherapy in metastatic melanoma.
Guida M, Riccobon A, Biasco G, Ravaioli A, Casamassima A, Freschi A, Palma MD, Galligioni E, Nortilli R, Chiarion-Sileni V, Picozzo J, Romanini A, Nanni O, Ridolfi R; Italian Melanoma Intergroup (IMI). Guida M, et al. Melanoma Res. 2006 Aug;16(4):317-23. doi: 10.1097/01.cmr.0000200491.00841.5f. Melanoma Res. 2006. PMID: 16845327 Clinical Trial.
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.
O'Day SJ, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, Bondarenko IN, Queirolo P, Lundgren L, Mikhailov S, Roman L, Verschraegen C, Humphrey R, Ibrahim R, de Pril V, Hoos A, Wolchok JD. O'Day SJ, et al. Ann Oncol. 2010 Aug;21(8):1712-1717. doi: 10.1093/annonc/mdq013. Epub 2010 Feb 10. Ann Oncol. 2010. PMID: 20147741 Free article. Clinical Trial.
Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens.
Chiarion-Sileni V, Guida M, Ridolfi L, Romanini A, Del Bianco P, Pigozzo J, Brugnara S, Colucci G, Ridolfi R, De Salvo GL; Italian Melanoma Intergroup (IMI). Chiarion-Sileni V, et al. Br J Cancer. 2011 Jun 7;104(12):1816-21. doi: 10.1038/bjc.2011.178. Epub 2011 May 24. Br J Cancer. 2011. PMID: 21610711 Free PMC article. Clinical Trial.
212 results